Will require private insurers and Medicare Part D plans to cover Naloxone without co-pays or deductibles.

Requires that private insurers and Medicare Part D plans cover Naloxone without any co-pay or deductible requirements

The bill would require private insurers and Medicare Part D plans to provide Naloxone coverage without patient cost-sharing.

Shaheen, Hassan Renew Efforts to Authorize Billions to Combat Substance Use Disorder
primary · press_release · model gpt-5.5

legacy_unverified · Source version not recorded · locator unknown

GovInfo lists S. 4895 as introduced by Sen. Jeanne Shaheen on June 24, 2026, read twice, and referred to the Senate Committee on Health, Education, Labor, and Pensions. The bill version is Introduced in Senate.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Latest official action found remains committee referral, with no enacted law or final passage found in the September 9-11, 2026 lookback. This shows serious concrete action by Shaheen, but the requirement has not been delivered as binding federal law.

unresolved same_term A for effort

S. 4895 (IS) - Turn the Tide Act - GovInfo Content Details
secondary · model gpt-5.5 · confidence 93%

legacy_unverified · Source version not recorded · locator unknown

Section 7 would require group health plans and health insurance issuers to cover at least one opioid overdose reversal agent without cost-sharing, and would require Medicare Part D prescription drug plans and MA-PD plans to impose no cost-sharing for at least one brand or generic opioid overdose reversal agent starting in plan year 2027.

Unverified model/legacy excerpt; not proof. AI summary (separate from source): The introduced bill text directly matches the commitment's substance for private insurance and Medicare Part D, but because the bill is only introduced/referred, it supports an unresolved status rather than delivery.

unresolved same_term A for effort

S. 4895 (IS) - Turn the Tide Act
secondary · model gpt-5.5 · confidence 95%